Lesson plan

Dalpiciclib

Dalpiciclib is a drug for the treatment of various forms of cancer. In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy. Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms.

Back to article

Article summary

Dalpiciclib is a drug for the treatment of various forms of cancer. In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy. Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.